Enlivex Therapeutics Earning Date (ENLV)

USA |NASDAQ |USD |ADR

ENLV Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Feb 26, 2022 (est) Dec 31, 2021 - $-0.19 $-0.43
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Feb 26, 2022 (est) Dec 31, 2021 - $0.00 $0.00

Enlivex Therapeutics's next estimated earnings date (based on same quarter last year's date) is Feb 26, 2022 for the fiscal quarter ending Dec 31, 2021.

ENLV Earnings Date & History Chart

ENLV Earnings & Revenue Forecast

ENLV Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 0 $0.00 $0.00 $0.00

ENLV Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-1.54 $-1.54 $-1.54

ENLV Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 1 $0.00 $0.00 $0.00

ENLV Earnings Date & Revenue History

ENLV Earnings History

|
Show More
Show More

ENLV Revenue History

|
Show More
Show More

Enlivex Therapeutics Next Earnings Date & Report

ENLV Nov 2021 (FQ) Earnings Date & Report Preview

ENLV's next estimated earnings date (based on same quarter last year's report date) is Feb 26, 2022 for the fiscal quarter ending Dec 31, 2021.

Enlivex Therapeutics Previous Earnings Dates & Reports

ENLV Previous Earnings Date & Report Recap: Sep 2021 (FQ)

Enlivex Therapeutics's previous earnings date was Nov 19, 2021 for its fiscal quarter ended Sep 30, 2021.

ENLV's earnings per share (EPS) was $-0.19, beating the consensus analysts forecast of $-0.21 by 9.52%.

The EPS was lower than the previous fiscal quarter (Jun 2021) by 11.76%, and lower than the same period a year before (Sep 2020) by 18.75%.

Revenues were $0.00.

The company reported a net income of $-3.42M.

Free cash flow for the quarter was $-4.32M , compared to $-4.71M last quarter and $-2.73M a year before.

ENLV ended the quarter with $636.00K in total debt, an increase of 202.86% compared to the previous quarter, and a decrease of -6.74% compared to the same quarter a year before.

ENLV Previous Earnings Date & Report Recap: Dec 2020 (FY)

Enlivex Therapeutics's previous annual earnings date was Feb 26, 2021 for its fiscal year ended Dec 31, 2020.

ENLV's earnings per share (EPS) was $-0.89, missing the consensus analysts forecast of $-0.72 by 23.61% , and higher than the previous year's EPS (Dec 2019) by -33.97%.

Revenues were $0.00.

The company reported a net income of $-11.82M.

Enlivex Therapeutics reported a free cash flow of $-12.03M for its fiscal year, compared to $-7.23M a year ago.

The company ended the fiscal year with $203.00K in total debt, an increase of 65.04% compared to the previous year.